This brief examines the implications of rising prescriptions for costly GLP-1 drugs for state Medicaid programs as more states consider covering the drugs for weight loss. It examines recent trends in Medicaid prescriptions and gross spending on GLP-1s, and explores the potential implications of expanding coverage obesity drugs for Medicaid programs.
from KFF https://ift.tt/t6Qy1RG
from KFF https://ift.tt/t6Qy1RG
Comments :
Post a Comment